Multiple U.S. IPOs are scheduled to price and begin trading in October 2026, including TRex Bio targeting $125 million, Retension Pharmaceuticals at $40 million, and Iambic Therapeutics aiming for up to $150 million, with additional filings from biotech and AI-adjacent firms. The 2026 IPO pipeline shows 125 deals priced year-to-date through early October amid Nasdaq gains of 35%, though some larger offerings like Oura have been postponed due to volatility. Key near-term catalysts include Anthropic’s reported November marketing push and ongoing S-1 activity that could support further listings before year-end. Market-implied odds reflect trader assessment of execution risk in the current rate and sentiment environment.